Immunoassay signal amplification: bold new solutions for existing ELISAs

Wednesday 29 April 2026
07:00 [PDT]  10:00 [EDT]  15:00 [BST]
Alternative time zones

Discover how to increase your immunoassay sensitivity and boost your biomarker research.

In this webinar, Peter Stenlund from Cavidi (Uppsala, Sweden) lays out the working principle for a new solution to improve signal amplification, known as BOLD (Binding Oligo Ladder Detection), revealing how this process can be integrated into existing ELISA protocols and optimized for a variety of settings and desired outcomes. Peter then moves on to demonstrate the effectiveness of BOLD in a research setting, detecting ultra-low levels of cardiac troponin I (cTnI), a key protein in cardiac research, for which BOLD achieved a 180-fold sensitivity improvement in a human cTnI sandwich ELISA.

Can’t see the form below? Register for the webinar here.

REGISTER NOWWhat will you learn?Who may this interest?Speaker

What will you learn?

  • Step-by-step mechanics behind BOLD signal amplification, from antibody conjugation to signal generation
  • How to integrate BOLD into existing ELISA protocols with minimal adjustments, including optimizations for capture/detector antibodies and temperature flexibility
  • How Exazym®’s BOLD signal amplification technology works within standard sandwich ELISA workflows to achieve a 180-fold improvement in cardiac troponin I detection sensitivity
  • How the cTnI detection limit was lowered to 0.07 pg/mL, enabling detection of heart injury at its earliest molecular stages
  • Real-world impact of ultra-sensitive cTnI detection: identifying cardiotoxic effects sooner in drug development, unlocking new insights into heart disease progression and improving patient care through earlier risk detection

Who may this interest?

  • Assay developers looking to enhance existing sandwich ELISA sensitivity without investing in new instrumentation
  • Cardiovascular researchers seeking ultra-sensitive detection of cardiac troponin I beyond the reach of conventional ELISA
  • Scientists and lab managers in biomarker discovery, professionals in drug development and CROs requiring improved cTnI sensitivity
  • Researchers in cardiology, drug safety monitoring and precision diagnostics, working with low-abundance cardiac biomarkers
  • Scientists in clinical development and clinical diagnostics needing to detect cardiotoxic effects at lower doses and earlier timepoints

Speaker

Peter Stenlund

Principal Scientist

Cavidi AB

Peter Stenlund is a protein chemist with a PhD in biochemistry from Umeå University (Sweden). His career spans roles as a senior lecturer, postdoctoral scientist in the U.S. and development scientist at Biacore (Uppsala, Sweden), as well as senior scientist positions at Octapharma (Lachen, Switzerland) and Galderma (Lausanne, Switzerland). He brings deep expertise in analytical development for protein drug characterization. As principal scientist at Cavidi AB, Stenlund now leads innovation in ultra-sensitive immunoassay solutions, making him the ideal guide for this technical deep dive into BOLD signal amplification.

 

In association with Cavidi.